Aclaris Therapeutics (ACRS) Tops Q1 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Aclaris Therapeutics (ACRS) Tops Q1 EPS by 9c

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

May 10, 2022 7:00 AM EDT

Clinical Sites Activated for Phase 2b Trial of ATI-1777April Capital Raise Extends Cash Runway Through End of 2025

WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2022 and provided a corporate update.

We have continued to progress our clinical programs, including activating multiple clinical sites in... More